Our top pick for
Building a portfolio
Aeglea BioTherapeutics, Inc is a biotechnology business based in the US. Aeglea BioTherapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea BioTherapeutics employs 90 staff and has a market cap (total outstanding shares value) of USD$376 million.
|52-week range||USD$4.91 - USD$11.38|
|50-day moving average||USD$7.7094|
|200-day moving average||USD$7.9371|
|Wall St. target price||USD$15.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.299|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-59,638,000|
|Return on assets TTM||-41.61%|
|Return on equity TTM||-80.93%|
|Market capitalisation||USD$376 million|
TTM: trailing 12 months
There are currently 2.0 million Aeglea BioTherapeutics shares held short by investors – that's known as Aeglea BioTherapeutics's "short interest". This figure is 11.4% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Aeglea BioTherapeutics shares can be evaluated.
Aeglea BioTherapeutics's "short interest ratio" (SIR) is the quantity of Aeglea BioTherapeutics shares currently shorted divided by the average quantity of Aeglea BioTherapeutics shares traded daily (recently around 195250.96711799). Aeglea BioTherapeutics's SIR currently stands at 10.34. In other words for every 100,000 Aeglea BioTherapeutics shares traded daily on the market, roughly 10340 shares are currently held short.
However Aeglea BioTherapeutics's short interest can also be evaluated against the total number of Aeglea BioTherapeutics shares, or, against the total number of tradable Aeglea BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeglea BioTherapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aeglea BioTherapeutics shares in existence, roughly 40 shares are currently held short) or 0.0448% of the tradable shares (for every 100,000 tradable Aeglea BioTherapeutics shares, roughly 45 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Aeglea BioTherapeutics.
Find out more about how you can short Aeglea BioTherapeutics stock.
We're not expecting Aeglea BioTherapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aeglea BioTherapeutics's shares have ranged in value from as little as $4.91 up to $11.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea BioTherapeutics's is 1.6837. This would suggest that Aeglea BioTherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Steps to owning and managing NSE, with 24-hour and historical pricing before you buy.
Steps to owning and managing NPA, with 24-hour and historical pricing before you buy.
Steps to owning and managing NFH, with 24-hour and historical pricing before you buy.
Steps to owning and managing NEP, with 24-hour and historical pricing before you buy.
Steps to owning and managing NEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing NTST, with 24-hour and historical pricing before you buy.
Steps to owning and managing NSYS, with 24-hour and historical pricing before you buy.
Steps to owning and managing NOA, with 24-hour and historical pricing before you buy.
Steps to owning and managing NMM, with 24-hour and historical pricing before you buy.
Steps to owning and managing NMCI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.